6/30/23, 12:09 AM VA Cooperative Study Pathway Feedback Search Clinical Topics Home Studies VA Cooperative Study VA Cooperative Study Trial question What is the role of aspirin in male patients with unstable angina? Study design Multi-center Double blinded RCT Population 1266 male patients Inclusion criteria: male patients with unstable angina Key exclusion criteria: congestive HF NYHA IV, tachyarrhythmia, anemia, contraindications to aspirin, bleeding tendency, myocardial infarction within 6 weeks, or other illness that might limit 1 year survival Interventions N=625 aspirin (324 mg in buffered solution daily for 12 weeks) N=641 placebo (matching placebo daily for 24 weeks) Primary outcome Death or acute MI 10.1 % 10.1 7.6 % 5.0 % 5 Significant decrease 2.5 % NNT = 20 0.0 % Aspirin Placebo Significant decrease in death or acute MI (5% vs. 10.1%; RR 0.49, 95% CI 0.22 to 0.76) Secondary outcomes Significant decrease in nonfatal myocardial infarction (3.4% vs. 6.9%; RR 0.49, 95% CI 0.15 to 0.83) Borderline significant decrease in death (1.6% vs. 3.3%; RR 0.48, 95% CI -0.01 to 0.97) Safety outcomes https://web.pathway.md/studies/recEiax7hRPyuWyZb 1/2 6/30/23, 12:09 AM VA Cooperative Study Pathway y No significant difference in gastrointestinal symptoms or evidence of blood loss. Conclusion In male patients with unstable angina, aspirin was superior to placebo with respect to death or acute MI. Reference Lewis HD Jr, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396-403. Open reference URL https://web.pathway.md/studies/recEiax7hRPyuWyZb 2/2